Biogen Ma Inc.

Sunesis Pharmaceuticals, Inc.

Ajinomoto Co., Ltd.

Xianglin Shi

Andrew S Thompson

Brian T Hopkins

Patrick R Conlon

Tracy J Jenkins

Timothy Raymond Chan

Ross A Miller

Michael J Humora

Xiongwei Cai

William F Kiesman

Yannick Fillon

Daisuke Takahashi

Taisuke Ichimaru

Robert S Gronke

J Michael Macphee

Michael J Macphee

Jimin Yang

Xuan Zhou

Firoz Antia

Wuming Yan

Hong Jiang

Takuya Hamagaki

Hien Nguyen

Andrew Thompson

The present disclosure describes a convergent liquid phase process for manufacturing oligonucleotides by coupling two or more oligonucleotide fragments, each of which have two or more nucleotides. Also provided by the present disclosure are reaction steps involved the convergent liquid phase process.

Convergent liquid phase syntheses of oligonucleotides

The invention herein describes a solid-phase synthetic method for preparing thiolated oligonucleotides without needing a capping step. The methods of the invention comprises repetition of a three-reaction per cycle, namely detritylation, coupling and sulfurization, without a capping step. In some embodiments, the synthetic methods of the present invention can be used for preparing an anti-sense oligonucleotide.

Synthesis of thiolated oligonucleotides without a capping step

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Pyrimidinyl tyrosine kinase inhibitors

The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.

Inhibitors of Bruton's tyrosine kinase

Growing community of inventors

Cambridge, MA, United States of America

Xianglin Shi